Long way to go: Progress of orphan drug accessibility in China from 2017 to 2022

Introduction: Over 400 million patients worldwide suffer from rare diseases. Access to orphan drugs is, therefore, crucial for this population. China has been actively working on improving orphan drug accessibility in the past decades, especially since 2018 when the First National List of Rare Disea...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Frontiers in Pharmacology
المؤلفون الرئيسيون:	Jia Liu, Yue Yu, Mingkang Zhong, Chunlai Ma, Rong Shao
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Frontiers Media S.A. 2023-03-01
الموضوعات:	orphan drug rare disease accessibility availability affordability China
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1138996/full

مواد مشابهة

Patient access to orphan drugs in France
حسب: Marion Bourdoncle, وآخرون
منشور في: (2019-02-01)

Orphan drug policy analysis in China
حسب: Meilin Liu, وآخرون
منشور في: (2024-06-01)

Orphan drugs in Italy: availability and time-to-access at regional level
حسب: Maria Lucia Marino, وآخرون
منشور في: (2023-12-01)

Utilization and affordability of health insurance coverage for rare disease drugs in a first-tier city in Northeast China from 2018 to 2021: a study based on the health insurance claims database
حسب: Yaqun Wang, وآخرون
منشور في: (2024-07-01)

Analysis of patient access to orphan drugs in Turkey
حسب: Güvenç Koçkaya, وآخرون
منشور في: (2021-02-01)

Current Problems in Provision of Orphan Drugs and Ways to Solve Them
حسب: Alexei S. Kolbin, وآخرون
منشور في: (2016-09-01)

International comparison of availability for orphan drugs: focused on approved orphan drugs in South Korea
حسب: Eun Young Shin, وآخرون
منشور في: (2024-12-01)

Current Status and Prospect of Orphan Drugs for Rare Skin Diseases in China
حسب: ZHANG Shan, وآخرون
منشور في: (2023-04-01)

Trends in orphan medicinal products approvals in the European Union between 2010–2022
حسب: Luísa Bouwman, وآخرون
منشور في: (2024-02-01)

Practice of the Qualification and Recognition for Orphan Drugs in the World and its Inspiration
حسب: ZHU Xiaohong, وآخرون
منشور في: (2022-07-01)

EMA approved orphan medicines since the implementation of the orphan legislation
حسب: Eveliina Hahl, وآخرون
منشور في: (2025-06-01)

REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS
حسب: Andrey Vladislavovich Pavlysh, وآخرون
منشور في: (2015-09-01)

Evidence from systematic reviews on policy approaches to improving access to medicines
حسب: Celestino Kuchena, وآخرون
منشور في: (2023-07-01)

Survey and analysis of accessibility, availability, and affordability of topical glaucoma medicines
حسب: Shalini Virani, وآخرون
منشور في: (2024-02-01)

Visual Research of Global Orphan Drug from a Bibliometric Perspective
حسب: Wen X, وآخرون
منشور في: (2025-05-01)

« Orphans ». Hyponym for rare diseases, but not so ultra-rare.
حسب: Nor El Houda KHELIF, وآخرون
منشور في: (2025-06-01)

Towards a sustainable rare disease and orphan drug ecosystem in Saudi Arabia: policy insights from a multi-stakeholder workshop
حسب: Ghada Mohammed Abozaid, وآخرون
منشور في: (2025-05-01)

Cross-national comparative study of orphan drug policies in Saudi Arabia, the United States, and the European Union
حسب: Bander Balkhi, وآخرون
منشور في: (2023-09-01)

Development of orphan drugs for rare diseases
حسب: Han-Wook Yoo
منشور في: (2024-07-01)

Optimizing Patient Access to Orphan Medicinal Products: Lessons from Central and Eastern Europe
حسب: Tomasz Kluszczynski, وآخرون
منشور في: (2025-05-01)

Features of intellectual property protection mechanisms on the example of orphan drugs circulation
حسب: D. S. Yurochkin, وآخرون
منشور في: (2022-01-01)

Current Status of Drug Development and Implementation for Diseases Included in the Second Catalog of Rare Diseases
حسب: LI Kexin, وآخرون
منشور في: (2023-10-01)

Research of Accessibility of Rare Disease Drugs Based on the China's First List of Rare Diseases
حسب: LIU Qingyang, وآخرون
منشور في: (2023-11-01)

Study on Drug List and Accessibility of Rare Diseases Based on the China′s Second List of Rare Diseases
حسب: LIU Qingyang, وآخرون
منشور في: (2024-04-01)

Generic orphan drug substitution: a critical analysis of global practices and Saudi Arabia’s perspective
حسب: Yousif S. Alakeel, وآخرون
منشور في: (2024-04-01)

Perception of Availability, Accessibility, and Affordability of COVID-19 Vaccines and Hesitancy: A Cross-Sectional Study in India
حسب: Akshay Ayappan, وآخرون
منشور في: (2022-11-01)

Expenditure trends of orphan drugs in Serbia: 8-Year analysis of orphan drug market in Serbia
حسب: Pejčić Ana V., وآخرون
منشور في: (2016-01-01)

Negotiating Medical Insurance Drug Prices: The Role in Reducing Costs of Orphan Drugs for Rare Diseases
حسب: Jinmiao Lu, وآخرون
منشور في: (2023-12-01)

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
حسب: Liz Morrell, وآخرون
منشور في: (2017-08-01)

Strategic discussion on funding and access to therapies targeting rare diseases in Spain: an expert consensus paper
حسب: N. Zozaya, وآخرون
منشور في: (2023-02-01)

A comparative study of orphan drug prices in Europe
حسب: Katherine Eve Young, وآخرون
منشور في: (2017-01-01)

Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen
حسب: Viviana Giannuzzi, وآخرون
منشور في: (2017-04-01)

Treatment access and satisfaction on disease-modifying therapies of neuromyelitis optica spectrum disorder patients in China: a cross-sectional survey
حسب: Yue Yu, وآخرون
منشور في: (2024-03-01)

Public spending on orphan medicines: a review of the literature
حسب: Margit Gombocz, وآخرون
منشور في: (2020-12-01)

Crowd Funding for Orphan Drugs: The Case of Baby Pia
حسب: Wim Pinxten
منشور في: (2021-12-01)

Variables affecting pricing of orphan drugs: the Italian case
حسب: Claudio Jommi, وآخرون
منشور في: (2021-10-01)

Just Treatment of Orphans as Viewed by Quran Interpreters
حسب: Muhammad Moradi, وآخرون
منشور في: (2020-12-01)

Quantifying the persisting orphan-drug shortage public health crisis in the United States
حسب: Szymon Jarosławski, وآخرون
منشور في: (2017-01-01)

Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries
حسب: Szczepan Jakubowski, وآخرون
منشور في: (2024-03-01)

Efficacy and safety of compassionate use for rare diseases: a scoping review from 1991 to 2022
حسب: Jiayu Wu, وآخرون
منشور في: (2023-11-01)